期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

噻唑烷二酮类药物的安全性概述 被引量：3

Security overview of TZDs
下载PDF
导出
作者 程佳芬 吴国亭
机构地区 同济大学附属第十人民医院内分泌科
出处 《同济大学学报（医学版）》 CAS 2010年第5期102-105,共4页 Journal of Tongji University(Medical Science)
基金 上海市科委资助项目(07411963100)
关键词 噻唑烷二酮 2型糖尿病 安全性
分类号 R98 [医药卫生—药品]
  • 相关文献

参考文献16

  • 1Nissen SE,Wolski K.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes[J].N Engl J Med,2007,356(24):2457-2471.
  • 2Su DH,Lai MY,Wu HP.Liver failure in a patient receiving rosiglitazone therapy[J].Diabet Med,2006,23(1):105-106.
  • 3Kahn SE,Haffner SM,Heise MA,et al.Glycemic durability of rosiglitazone,metformin,or glyburide monotherapy[J].N Engl J Med,2006,355(23):2427-2443.
  • 4Dargie HJ,Hildebrandt PR,Riegger GA,et al.A randomized,placebo-controlled trial assessing the effects of rosiglitazone on echocardiograohic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class Ⅰ or Ⅱ Heart Failure[J].J Am Coll Cardiol,2007,49:1696-1704.
  • 5Berlie HD,Kalus JS,Jaber LA.Thiazolidinediones and the risk of edema:a meta-analysis[J].Diabetes Res Clin Pract,2007,76(2):279-289.
  • 6Karalliedde J,Buckingham R,Starkie M,et al.Effect of various diuretic treat-ments on rosiglitazone-induced fluid retention[J].J Am Soc Nephrol,2006,17(12):3482-3490.
  • 7Nesto RW,Bell D,Bonow RO,et al.Thiazolidinedione use,fluid retention,and congestive heart failure:a consensus statement from the American Heart Association and American Diabetes Association[J].Diabetes Care,2004,27(1):256-263.
  • 8Home PD,Pocock SJ,Beck-Nielsen H,et al.Rosiglitazone evaluated for cardio-vascular outcomes:an interim analysis[J].N Engl J Med,2007,357(1):28-38.
  • 9Tang WH,Maroo A.PPARgamma agonists:safety issues in heart failure[J].Diabetes Obes Metab,2007,9(4):447-454.
  • 10Grey A.Thiazolidinedione-induced skeletal fragilitymechanisms and implications[J].Diabetes Obes Metab,2008,10(1111):1463-1466.

二级参考文献22

  • 1杨金奎.ADOPT研究的最新结果[J].国际内分泌代谢杂志,2007,27(1):1-3. 被引量：6
  • 2Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone mefformin or glyburide monotherapy [J].N Engl J Med, 2006, 355: 2427 - 2443.
  • 3Nathan DM. Thiazolidinediones for initial treatment of type 2 diabetes [ J ]. N Engl J Med, 2006, 355: 2477 - 2480.
  • 4Berger J, Moiler DE. The mechanisms of action of PPARs [ J ]. Annu Rev Med,2002,53:409 - 435.
  • 5Rzonea SO,Suva IJ, Gaddy D, et al. Bone is a target for the antidiabetic compound rosiglitazone[J]. Endocrinology, 2004, 145:401 - 406.
  • 6Khan E, Abu-Amer Y. Activation of peroxisome proliferator-activated receptor-gamma inhibits ditierentiatlon of preostcoblasts [J]. J Lab Clin Med,2003,142:29 -34.
  • 7Soreceanu MA, Miao D, Bai XY, et al. Rosiglitazone impacts negatively on bone by promoting osteoblastf osteocyte apoptosis [J]. J Endocrinol, 2004, 183: 203 - 216.
  • 8Lecka-Czemik B, Moerman EJ, Grant DF, et al. Divergent effects of selective peroxisome proliferators activated receptor-gamma 2 ligands on edipocyte versus osteoblast differentiation[J]. Endocrinology, 2002,143 : 2376 - 2384.
  • 9Sakaguchi K, Morita L, Murota S. Relationship between the ability to support differentiation of osteoclast-like cells and adipogenesis in murine stromal cells derived from bone marrow [J]. Prostaglandins Leukot Essent Fstty Acids,2006,2 ( 5 ) : 319 - 327.
  • 10Neer RM, Arnaud CD, Zaua Eetta JR, et al. Effect of parathyroid hormone ( 1 - 34 ) on fractures and bone mineral density in post-menopausal women with osteoporosis [J]. New Eng J Med, 2001, 344 (19) : 1434.

共引文献10

同被引文献58

  • 1刘海花.新的胰岛素增敏剂:吡格列酮应用进展[J].药物流行病学杂志,2004,13(5):240-242. 被引量：6
  • 2廖洪利,吴秋业,叶光明,蔡灵芝.芒果苷药理研究进展[J].天津药学,2005,17(2):50-52. 被引量：35
  • 3孟凡良.2型糖尿病应用吡格列酮和二甲双胍的作用比较[J].医药论坛杂志,2006,27(6):5-6. 被引量：2
  • 4李洪梅.α-葡萄糖苷酶抑制剂的临床应用[J].中国医刊,2007,42(10):19-21. 被引量：33
  • 5Chen YW, Chen YC, Wu CJ, et al. Massive Bilateral Pleural Effusion Associated with Use of Pioglitazone [J]. Clinical Therapeutics, 2008, 30(8):1485-1489.
  • 6Tan M, Johns D, Guillermo Gonzalez,et al. Effects of Pioglitazone and Glimepiride on Glycemic Control and Insulin Sensitivity in Mexican Patients with Type 2 Diabetes Mellitus:A Multicenter, Randomized,Double-Blind, Parallel-Group Trial[J].Clinical therapeutics,2004,26(5):680-93.
  • 7Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: a Meta-analysis[J].Diabetes Res Clin Prac,2007,76( 2):279-289.
  • 8Kawamori R, Kadowaki T, Onji M,et al.Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: Postmarketing surveillance study in Japan[J].Diabetes Research and Clinical Practice,2007,76:229-235.
  • 9Bhat R, Bhansali A,Bhadada S,et al. Effect of pioglitazone therapy in lean typel diabetes mellitus[J]. Diabetes Research and Clinical Practice,2007,78:349-354.
  • 10Dargie H J, Hildebrandt PR, Riegger GA,et al.A random ized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiog raohic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional and class I and II Heart Failure[J].J Am Coil Cardiol,2007,49:1696-1704.

引证文献3

二级引证文献27

同济大学学报（医学版）
2010年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部